Insulin glargine and cancer risk: An opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy

Krystal L. Edwards, Daniel M. Riche, Jeffrey Stroup, Jennifer D. Goldman-Levine, Rosalyn S. Padiyara, L. Brian Cross, Michael P. Kane

Research output: Contribution to journalComment/debate

7 Citations (Scopus)

Abstract

Diabetes mellitus has reached epidemic proportions worldwide, eliciting extensive research on both the disease process and its treatment. Regardless of diabetes type, the progressive nature of the disease makes insulin the long-term mainstay of diabetes management. Recently, the insulin analog glargine was reported in several epidemiologic studies to be associated with an increased risk of cancer. Inconsistent study results and media attention have caused much angst and concern to health care professionals and the general population. A clear understanding of the current evidence is needed to adequately develop a patient-oriented risk:benefit assessment. Members of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy evaluated available evidence to provide guidance and discussion on the risk of cancer with insulin glargine use. We believe the current link between insulin glargine and cancer is tenuous but merits further evaluation. An independent analysis of all available glargine clinical trial data should be performed, and a vigorous postmarketing safety study of glargine should be conducted. Until more substantial data are available, however, neither the choice of initial insulin therapy nor insulin maintenance regimens should be influenced by the current information linking insulin glargine to cancer.

Original languageEnglish
Pages (from-to)955-965
Number of pages11
JournalPharmacotherapy
Volume30
Issue number9
DOIs
StatePublished - 1 Sep 2010

Fingerprint

Research
Neoplasms
Insulin
Insulin Glargine
Epidemiologic Studies
Diabetes Mellitus
Maintenance
Clinical Trials
Delivery of Health Care
Safety
Therapeutics
Population

Keywords

  • Cancer
  • Diabetes
  • Insulin
  • Insulin glargine
  • Oncology

Cite this

Edwards, Krystal L. ; Riche, Daniel M. ; Stroup, Jeffrey ; Goldman-Levine, Jennifer D. ; Padiyara, Rosalyn S. ; Cross, L. Brian ; Kane, Michael P. / Insulin glargine and cancer risk : An opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. In: Pharmacotherapy. 2010 ; Vol. 30, No. 9. pp. 955-965.
@article{41da6a4697924e2dbb1e0f4be85ba48a,
title = "Insulin glargine and cancer risk: An opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy",
abstract = "Diabetes mellitus has reached epidemic proportions worldwide, eliciting extensive research on both the disease process and its treatment. Regardless of diabetes type, the progressive nature of the disease makes insulin the long-term mainstay of diabetes management. Recently, the insulin analog glargine was reported in several epidemiologic studies to be associated with an increased risk of cancer. Inconsistent study results and media attention have caused much angst and concern to health care professionals and the general population. A clear understanding of the current evidence is needed to adequately develop a patient-oriented risk:benefit assessment. Members of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy evaluated available evidence to provide guidance and discussion on the risk of cancer with insulin glargine use. We believe the current link between insulin glargine and cancer is tenuous but merits further evaluation. An independent analysis of all available glargine clinical trial data should be performed, and a vigorous postmarketing safety study of glargine should be conducted. Until more substantial data are available, however, neither the choice of initial insulin therapy nor insulin maintenance regimens should be influenced by the current information linking insulin glargine to cancer.",
keywords = "Cancer, Diabetes, Insulin, Insulin glargine, Oncology",
author = "Edwards, {Krystal L.} and Riche, {Daniel M.} and Jeffrey Stroup and Goldman-Levine, {Jennifer D.} and Padiyara, {Rosalyn S.} and Cross, {L. Brian} and Kane, {Michael P.}",
year = "2010",
month = "9",
day = "1",
doi = "10.1592/phco.30.9.955",
language = "English",
volume = "30",
pages = "955--965",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Wiley-Blackwell",
number = "9",

}

Insulin glargine and cancer risk : An opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. / Edwards, Krystal L.; Riche, Daniel M.; Stroup, Jeffrey; Goldman-Levine, Jennifer D.; Padiyara, Rosalyn S.; Cross, L. Brian; Kane, Michael P.

In: Pharmacotherapy, Vol. 30, No. 9, 01.09.2010, p. 955-965.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Insulin glargine and cancer risk

T2 - An opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy

AU - Edwards, Krystal L.

AU - Riche, Daniel M.

AU - Stroup, Jeffrey

AU - Goldman-Levine, Jennifer D.

AU - Padiyara, Rosalyn S.

AU - Cross, L. Brian

AU - Kane, Michael P.

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Diabetes mellitus has reached epidemic proportions worldwide, eliciting extensive research on both the disease process and its treatment. Regardless of diabetes type, the progressive nature of the disease makes insulin the long-term mainstay of diabetes management. Recently, the insulin analog glargine was reported in several epidemiologic studies to be associated with an increased risk of cancer. Inconsistent study results and media attention have caused much angst and concern to health care professionals and the general population. A clear understanding of the current evidence is needed to adequately develop a patient-oriented risk:benefit assessment. Members of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy evaluated available evidence to provide guidance and discussion on the risk of cancer with insulin glargine use. We believe the current link between insulin glargine and cancer is tenuous but merits further evaluation. An independent analysis of all available glargine clinical trial data should be performed, and a vigorous postmarketing safety study of glargine should be conducted. Until more substantial data are available, however, neither the choice of initial insulin therapy nor insulin maintenance regimens should be influenced by the current information linking insulin glargine to cancer.

AB - Diabetes mellitus has reached epidemic proportions worldwide, eliciting extensive research on both the disease process and its treatment. Regardless of diabetes type, the progressive nature of the disease makes insulin the long-term mainstay of diabetes management. Recently, the insulin analog glargine was reported in several epidemiologic studies to be associated with an increased risk of cancer. Inconsistent study results and media attention have caused much angst and concern to health care professionals and the general population. A clear understanding of the current evidence is needed to adequately develop a patient-oriented risk:benefit assessment. Members of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy evaluated available evidence to provide guidance and discussion on the risk of cancer with insulin glargine use. We believe the current link between insulin glargine and cancer is tenuous but merits further evaluation. An independent analysis of all available glargine clinical trial data should be performed, and a vigorous postmarketing safety study of glargine should be conducted. Until more substantial data are available, however, neither the choice of initial insulin therapy nor insulin maintenance regimens should be influenced by the current information linking insulin glargine to cancer.

KW - Cancer

KW - Diabetes

KW - Insulin

KW - Insulin glargine

KW - Oncology

UR - http://www.scopus.com/inward/record.url?scp=77956136910&partnerID=8YFLogxK

U2 - 10.1592/phco.30.9.955

DO - 10.1592/phco.30.9.955

M3 - Comment/debate

C2 - 20795850

AN - SCOPUS:77956136910

VL - 30

SP - 955

EP - 965

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 9

ER -